Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Eshelman v. Auerbach et al
Case Number:
7:16-cv-00018
Court:
Nature of Suit:
Judge:
Firms
- Clare Locke
- Hedrick Gardner
- Horton & Mendez
- Latham & Watkins
- McGuireWoods
- Moore & Van Allen
- Murchison Taylor
- Wilkinson Stekloff
- Womble Bond
- Young Moore
Companies
Sectors & Industries:
-
March 02, 2020
Puma Biotech Can't Upend $22M Loss In Exec's Libel Case
A biotech company found liable for defaming a pharmaceutical executive aiming to gain control of it was denied a new trial Monday by a federal judge who said overwhelming evidence shows the company fabricated the North Carolina businessman's links to fraud.
-
March 19, 2019
Puma Biotech Owes $22M For Libel In Proxy Fight, Jury Says
A North Carolina federal jury has found that Puma Biotechnology Inc. defamed Pharmaceutical Product Development LLC's former CEO during a proxy fight by telling the public he had been "involved in clinical trial fraud," awarding the former PPD head $22.35 million.